Registration deadline is March 11, 2020 – 11:30 a.m. (ET)
March 11, 2020 – 12 p.m. - 1 p.m. (ET)
|Pacific Time||9:00 a.m. – 10:00 a.m.|
|Mountain Time||10:00 a.m. – 11:00 a.m.|
|Central Time||11:00 a.m. – 12:00 p.m.|
|Eastern Time||12:00 p.m. – 1:00 p.m.|
|Atlantic Time||1:00 p.m. – 2:00 p.m.|
|Newfoundland Time||1:30 p.m. – 2:30 p.m.|
SAC Members and Associates
*All registered participants must be SAC members/associates
Cancellation Policy: Because we have limited spaces available for participants, if you are unable to attend the webinar you registered for, please contact Bev Cooper at email@example.com as soon as possible.
Intended audience: Speech-Language Pathologists, Audiologists, Speech and Hearing Assistant, Audiology Assistant, Students
This session pertains to: Pre-School (0-4), School Aged (5-17), Adult (18-64), Seniors (65+)
Level: Intermediate (Assumes that the participant has general familiarity with the literature and professional practice within the areas covered.)
Ototoxicity is broadly defined as the tendency of certain substances, whether systemic or topical, to cause functional impairment and cellular damage to tissues of the inner ear and especially the end organs responsible for vestibular and cochlear function. While the number of medications recognized to cause ototoxicity continues to increase yearly, specific emphasis is focused on ototoxicity from systemic aminoglycoside and platinum-based chemotherapies. The mechanisms and risk factors for the development of ototoxicity will be discussed. Until basic science research provides us with new strategies for its prevention (including hair cell regeneration), there will be a continued need to monitor patients appropriately in order to identify early changes in cochleovestibular function and be able to act accordingly to prevent further injury. Therapeutic monitoring protocols for the early recognition of aminoglycoside and chemotherapy based ototoxicity will be further discussed. New treatment strategies for the prevention of cochleotoxicity from chemotherapeutic agents is mentioned. Medicolegal ramifications may also follow in circumstances where ototoxicity could have been prevented and appropriate informed consent was not provided.
- Review our knowledge of what classes of drugs and medications can cause ototoxicity.
- Understand the mechanisms and risk factors for chemotherapeutic and aminoglycoside induced ototoxicity.
- To learn the symptoms/signs that help distinguish a unilateral from a bilateral peripheral vestibular loss.
- To learn protocols for audiometric and vestibular monitoring during treatment.
- To learn the new research into otoprotective therapies.
This webinar is eligible for SAC CEEs (Category A).
Dr. John Rutka, MD, FRCSC
Dr Rutka is a professor of Otolaryngology-Head and Neck Surgery at the University of Toronto. He has been on active staff at the University Health Network (UHN) since 1986 with a subspecialty interest in otology/neurotology.
For 20 years Dr Rutka was the chief fellowship mentor for the TWJ Foundation (UK). He is currently the chief mentor for the Peter and Melanie Munk Foundation scholarship in otology/neurotolgy. In addition, Dr Rutka is the the co-director of the UHN Center for Advanced Hearing and Balance Testing and the Hertz Multidisciplinary Neurotology Clinic. His chief academic interests have been in areas of topical and systemic ototoxicty, canal based surgery for dizziness, the conservative management of patients with vestibular schwannomas, time trends in the surgery for chronic ear disease and recently the evaluation of dizziness in the head injured patient. His CV lists over 100 peer-reviewed publications and 4 text books in addition to numerous book chapters/supplements/non-peer reviewed articles.
Accessing the Webinar
GoToWebinar is used to host this webinar. Before joining, be sure to check system requirements to avoid any connection issues.
Note about internet: We suggest you DO NOT use a Wi-Fi connection to view the webinar as it can be unreliable and you may lose connectivity during the presentation.
|Access to SAC webinars, Lunch & Learns and webcasts are an exclusive benefit of SAC membership. Links to online SAC Professional Development opportunities are not to be shared with non-members/non-associates. SAC reserves the right to terminate participation of a non-member/associate in any SAC online Professional Development event.
Non-members or non-associates must join SAC in order to have access to SAC online professional development. Information on joining SAC can be found on our website at https://www.sac-oac.ca/membership-certification/become-member-0.